Highlights
- •Vasomotor symptoms increase by 3 months following premenopausal RRSO and persist but do not worsen by 12 months.
- •Almost all women report these vasomotor symptoms as “mild”.
- •Hormone therapy reduces but does not resolve vasomotor symptoms after RRSO.
- •Hormone therapy improves menopause related quality of life but not to pre-RRSO levels.
Abstract
Objective
To measure menopausal symptoms and quality of life up to 12 months after risk-reducing
salpingo-oophorectomy (RRSO) and to measure the effects of hormone therapy.
Methods
Prospective observational study of 95 premenopausal women planning RRSO and a comparison
group of 99 who retained their ovaries. Vasomotor symptoms and menopausal-related
quality of life (QoL) were measured by the Menopause-Specific QoL Intervention scale
at baseline, 3, 6 and 12 months. Chi-square tests measured differences in prevalence
of vasomotor symptoms between RRSO vs the comparison group and by hormone therapy
use. Change in QoL were examined with multilevel modelling.
Results
Three months after RRSO hot flush prevalence increased from 5.3% to 56.2% and night
sweats from 20.2% to 47.2%. Symptoms did not worsen between 3 and 12 months and remained
unchanged in the comparison group (p<0.001). After RRSO, 60% commenced hormone therapy.
However, 40% of hormone therapy uses continued to experience vasomotor symptoms. After
RRSO, 80% of non-hormone therapy users reported vasomotor symptoms. Regardless of
hormone therapy use, 86% categorized their vasomotor symptoms as “mild” after RRSO.
Following RRSO, Menopause-related QoL deteriorated but was stable in the comparison
group (adjusted coefficient = 0.75, 95%CI = 0.55-0.95). After RRSO, QoL was better
in hormone therapy users vs non-users (adjusted coefficient = 0.49, 95%CI = 0.20-0.78).
Conclusions
Vasomotor symptoms increase by 3 months after RRSO but do not worsen over the next
12 months. Hormone Therapy reduces but does not resolve vasomotor symptoms and may
improve QoL, but not to pre-oophorectomy levels.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Gynecologic OncologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Ovarian cancer statistics, 2018.CA Cancer J. Clin. 2018; 68: 284-296
- Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.Jama. 2017; 317: 2402-2416
- Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the prospective Lynch syndrome database.Gut. 2018; 67: 1306-1316
- Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-ooprhorectomy in BRCA1 or BRCA2 mutation carriers.JNCI. 2009; 101: 80-87
- Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.JAMA. 2010; 304: 967-975
- Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology.J. Natl. Compr. Cancer Netw. 2021; 19: 77-102
- Climacteric symptoms in women undergoing risk-reducing bilateral salpingo-oophorectomy.Climacteric. 2009; 25: 1-6
- Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer.J. Clin. Oncol. 2005; 23: 6890-6898
- The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation.Gynecol. Oncol. 2011; 121: 163-168
- Prophylactic oophorectomy versus screening: psychosocial outcomes in women at increased risk of ovarian cancer.Psychooncology. 2001; 10: 231-241
- Oral estrogen replacement therapy versus placebo for hot flushes.Cochrane Database Syst. Rev. 2002; 288CD002978
- Factors associated with use of hormone therapy after preventive oophorectomy in BRCA mutation carriers.Menopause. 2020; 27: 1396-1402
- Exploring factors that impact on uptake of risk-reducing bilateral salpingo-oophorectomy (RRBSO) in high- risk women.Menopause. 2020; 27: 26-32
- for the STRAW 10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging.Menopause. 2012; 19: 387-395
- What happens after menopause? (WHAM): protocol for a prospective, multicentre, age-matched cohort trial of risk-reducing bilateral salpingo-oophorectomy in high-risk premenopausal women.BMJ Open. 2017; 7e018758
- Further psychometric property development of the menopause-specific quality of life questionnaire and development of a modified version, MENQOL-intervention questionnaire.Maturitas. 2005; 50: 209-221
- A menopause-specific quality of life questionnaire: development and psychometric properties.Maturitas. 1996; 24: 161-175
- Evaluation of the menopause-specific quality of life questionnaire: a factor-analytic approach.Menopause. 2012; 19: 211-215
- The menopause-specific quality of life questionnaire: psychometric evaluation among breast cancer survivors.Menopause. 2011; 18: 289-295
- Moderate to severe vasomotor and sexual symptoms remain problematic for women aged 60 to 65 years.Menopause. 2015; 22: 694-701
- Duration of menopausal vasomotor symptoms over the menopause transition.JAMA Intern. Med. 2015;Feb 16; https://doi.org/10.1001/jamainternmed.2014.8063
- Clinical effects of early or surgical menopause.Obstet. Gynecol. 2020; 135: 853-868
- Moderate to severe vasomotor and sexual symptoms remain problematic for women aged 60 to 65 years.Menopause. 2018; 25: 1331-1338
- Menopause-specific questionnaire assessment in US population-based study shows negative impact on health-related quality of life.Maturitas. 2009; 62: 153-159
- Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: an NRG oncology/GOG study.Gynecol. Oncol. 2020; 156: 131-139
- Effects of bilateral salpingo-oophorectomy on menopausal symptoms and sexual functioning among women with a BRCA1 or BRCA2 mutation.Gynecol. Oncol. 2019; 152: 145-150
- Association of salpingectomy with delayed oophorectomy versus Salpingo-oophorectomy with quality of life in BRCA1/2 pathogenic variant carriers: a nonrandomized controlled trial.JAMA Oncol. 2021; (Online ahead of print)e211590https://doi.org/10.1001/jamaoncol.2021.1590
- HRT for women with premature ovarian insufficiency: a comprehensive review.Hum. Reprod. Open. 2017; 2017 (eCollection 2017)hox007https://doi.org/10.1093/hropen/hox007
- Clinical practice. Primary ovarian insufficiency.N. Engl. J. Med. 2009; 360: 606-614
- The impact of attitudes towards the menopause on women's symptom experience: a systematic review.Maturitas. 2010; 65: 28-36
- Obesity associates with vasomotor symptoms in postmenopause but with physical symptoms in perimenopause: a cross-sectional study.BMC Womens Health. 2017; 17: 126
- Vasomotor symptoms and menopause: findings from the study of women's health across the nation.Obstet. Gynecol. Clin. N. Am. 2011; 38: 489-501
- What I wish I'd known before surgery: BRCA carriers' perspectives after bilateral salipingo-oophorectomy.Familial Cancer. 2010; 10: 79-85
- High-risk premenopausal women's experiences of undergoing prophylactic oophorectomy: a descriptive study.Genet. Test. 2004; 8: 148-156
- What information do healthcare professionals need to inform premenopausal women about risk-reducing salpingo-oophorectomy?.Menopause. 2020; 27: 20-25
Article info
Publication history
Published online: July 23, 2021
Accepted:
July 18,
2021
Received in revised form:
July 15,
2021
Received:
May 24,
2021
Identification
Copyright
© 2021 Elsevier Inc. All rights reserved.
